On June 9, DotBio-B declined 5.04% in regular trading, trading at HK$171.6/share, with trading volume of HK$37.87 million. The stock continues its downward trend after a brief ASCO-driven rebound on June 5 proved short-lived.

The company staged a 6% bounce on June 5 supported by consecutive share buybacks and positive ASCO clinical data catalysts, including Phase I data for its B7-H4 ADC DB-1312/BG-C9074 partnered with BeiGene. However, the rebound failed to hold, with the stock falling 5.25% on June 8 as selling pressure overwhelmed buyback efforts. Despite repurchasing a cumulative 262,400 shares since late May totaling approximately HK$53.3 million year-to-date, the company has been unable to stem persistent outflows. Southbound funds have reduced holdings by approximately 2.86 million shares over the past 20 trading days, bringing their stake down to around 29.66% of issued shares.

The broader Biotechnology sector is under significant pressure today, with Innovent Bio down 4.37%, Akeso down 3.79%, Remegen down 3.49%, BeiGene down 2.33%, and SKB Bio down 1.57%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)